WO2014007421A1 - Culture composition for inducing activated t lymphocytes from peripheral blood, culture kit comprising the same, and method for inducing activated t lymphocytes from peripheral blood using the same - Google Patents
Culture composition for inducing activated t lymphocytes from peripheral blood, culture kit comprising the same, and method for inducing activated t lymphocytes from peripheral blood using the same Download PDFInfo
- Publication number
- WO2014007421A1 WO2014007421A1 PCT/KR2012/006318 KR2012006318W WO2014007421A1 WO 2014007421 A1 WO2014007421 A1 WO 2014007421A1 KR 2012006318 W KR2012006318 W KR 2012006318W WO 2014007421 A1 WO2014007421 A1 WO 2014007421A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- lymphocytes
- culture composition
- peripheral blood
- culture
- activated
- Prior art date
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 76
- 239000000203 mixture Substances 0.000 title claims abstract description 53
- 210000005259 peripheral blood Anatomy 0.000 title claims abstract description 39
- 239000011886 peripheral blood Substances 0.000 title claims abstract description 39
- 230000001939 inductive effect Effects 0.000 title claims abstract description 30
- 238000000034 method Methods 0.000 title claims abstract description 23
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims abstract description 26
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 claims abstract description 19
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 claims abstract description 19
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims abstract description 16
- 150000001768 cations Chemical class 0.000 claims abstract description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims abstract description 14
- 102000003951 Erythropoietin Human genes 0.000 claims abstract description 13
- 108090000394 Erythropoietin Proteins 0.000 claims abstract description 13
- 102000004877 Insulin Human genes 0.000 claims abstract description 13
- 108090001061 Insulin Proteins 0.000 claims abstract description 13
- 229940105423 erythropoietin Drugs 0.000 claims abstract description 13
- 229940125396 insulin Drugs 0.000 claims abstract description 13
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000002904 solvent Substances 0.000 claims abstract description 12
- 210000003714 granulocyte Anatomy 0.000 claims abstract description 9
- 102000007644 Colony-Stimulating Factors Human genes 0.000 claims abstract description 8
- 108010071942 Colony-Stimulating Factors Proteins 0.000 claims abstract description 8
- 229940047120 colony stimulating factors Drugs 0.000 claims abstract description 8
- 229940011671 vitamin b6 Drugs 0.000 claims abstract description 8
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000011726 vitamin B6 Substances 0.000 claims abstract description 6
- 235000019158 vitamin B6 Nutrition 0.000 claims abstract description 6
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 16
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 16
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims description 16
- 238000011534 incubation Methods 0.000 claims description 16
- 210000004369 blood Anatomy 0.000 claims description 14
- 239000008280 blood Substances 0.000 claims description 14
- 229930003270 Vitamin B Natural products 0.000 claims description 11
- 235000019156 vitamin B Nutrition 0.000 claims description 11
- 239000011720 vitamin B Substances 0.000 claims description 11
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 8
- 239000003146 anticoagulant agent Substances 0.000 claims description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims description 8
- 239000002771 cell marker Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical group O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 239000012153 distilled water Substances 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- CODNYICXDISAEA-UHFFFAOYSA-N bromine monochloride Chemical compound BrCl CODNYICXDISAEA-UHFFFAOYSA-N 0.000 claims description 3
- 235000008160 pyridoxine Nutrition 0.000 claims description 2
- 239000011677 pyridoxine Substances 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 description 19
- 238000003364 immunohistochemistry Methods 0.000 description 11
- 238000010186 staining Methods 0.000 description 11
- 230000024245 cell differentiation Effects 0.000 description 8
- 210000000265 leukocyte Anatomy 0.000 description 8
- 238000005119 centrifugation Methods 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 5
- 230000032823 cell division Effects 0.000 description 5
- 210000000601 blood cell Anatomy 0.000 description 4
- 239000000306 component Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 230000003204 osmotic effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- -1 and preferably Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 238000002659 cell therapy Methods 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 230000015271 coagulation Effects 0.000 description 2
- 238000005345 coagulation Methods 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000002093 peripheral effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 206010052234 Citrate toxicity Diseases 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 210000003850 cellular structure Anatomy 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 229960004177 filgrastim Drugs 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000002992 thymic effect Effects 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/38—Vitamins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/01—Modulators of cAMP or cGMP, e.g. non-hydrolysable analogs, phosphodiesterase inhibitors, cholera toxin
Definitions
- the present invention relates to a culture composition for inducing activated T lymphocytes from peripheral blood, a culture kit comprising the same, and a method for inducing activated T lymphocytes from peripheral blood using the same, and more particularly, to a culture composition for inducing CD3 and CD25 positive T cells by the directed differentiation of leukocytes obtained from peripheral blood, a culture kit comprising the same, and a method for inducing CD3 and CD25 positive T cells using the same .
- T cells also known as T lymphocytes, are derived from hematopoietic stem cells in bone marrow, differentiate in the thymus and migrate to peripheral lymphatic tissues . T cells are distributed in the spleen and all parts of the thymus in lymph nodes .
- T cells occupy 60-70% of lymphocytes in tissues or blood and the number of T cells is commonly slightly greater than that of B cells. While T cells cannot be morphologically distinguished from B cells, they can be identified and isolated by differences in cell surface antigens (CD4, CD8, CD3, or Thyl antigens in mice, and the like) .
- T cells are classified largely into CD4 + CD8 " T cells and CD4 " CD8 + T cells according to antigenic CD4 and CD8 molecules expressed on their surface.
- T cells are divided into several subgroups having different functions, including helper T cells and cells mediating delayed type hypersensitivity, belonging to the former, and killer T cells belonging to the latter, and the like.
- CD3 is a cell marker which is commonly expressed in all T lymphocytes and proves that unknown cells are T cells.
- CD25-expressing T cells are considered to be activated T lymphocytes (T cell subsets: A synopsis of the lecture by Dr. Steve Cobbold for the FHS Physiology Immunology Option 1/ Definitions and relationships of different T cell subsets http: //users .path. ox. ac . uk/ ⁇ scobbold/Teaching/TSUBSETS .pdf) .
- CD25-positive cells are activated T lymphocytes, and are known to have therapeutic effects on autoimmune diseases and tumors (Romagnoli Paola, Tellier Julie, Van Meerwijik Joost Pm: Genetic control of thymic development of CD4+, CD25+FoxP3+ regulatory T lymphocytes, Eur J Immunol, 2005 Dec; 35 (12) :3525-32) .
- T cells are a major type of cells mediating cellular immunity against cancer cells, viruses, or transplanted tissues or cells. In order to attack targets, T cells should be activated from a resting and nonproliferative state to an active and proliferatable state.
- hematopoiesis in the human body is a one-way process of differentiation from multipotential hematopoietic stem cells to functional mature differentiated cells, such as granulocytes, monocytes, lymphocytes, and the like, as shown in FIG. 1.
- An aspect of the present invention provides a culture composition for inducing activated T lymphocytes from peripheral blood.
- Another aspect of the present invention provides a culture kit for inducing activated T lymphocytes from peripheral blood. [0012] Another aspect of the present invention provides a method for inducing activated T lymphocytes using the culture composition and the culture kit.
- a culture composition for inducing activated T lymphocytes from peripheral blood comprising adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
- ATP adenosine triphosphate
- G-CSF Granulocyte colony-stimulating factors
- erythropoietin erythropoietin
- the induced T cells may be CD3 and CD25 cell marker positive .
- the divalent cation may be one or more selected from the group consisting of Zn 2+ , Cu 2+ , Mg 2+ , and Cr 2+ .
- the chloride may be one or more selected from the group consisting of potassium chloride and bromine chloride.
- the vitamin B may be vitamin B6.
- the solvent may be distilled water.
- the culture composition may comprise 10-15 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 80-100 mg of the chloride, 45-55 mg of vitamin B, 3-7 I.U. of insulin, 5-15 g of Granulocyte colony-stimulating factors (G-CSF), 5-15 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc .
- ATP adenosine triphosphate
- G-CSF Granulocyte colony-stimulating factors
- erythropoietin erythropoietin
- a culture kit for inducing activated T lymphocytes from peripheral blood comprising an airtight sterile container, which contains the above culture composition, and in which internal pressure is controlled to be equal to external pressure thereof.
- a method for inducing activated T lymphocytes from peripheral blood comprising: mixing blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into an airtight sterile container, which contains the culture composition, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
- the incubation may be carried out for a period of f om about 50 hours to about 200 hours.
- the incubation may be carried out at a temperature from about 37 to 39 °C.
- the induced T cells may be CD3 and CD25 cell marker positive .
- the culture kit of the present invention for inducing activated T lymphocytes from peripheral blood and the method for inducing activated T lymphocytes using the same, a large amount of activated T lymphocytes can easily be obtained from peripheral blood obtained from adults.
- the obtained activated T lymphocytes can be used in various fields associated with the treatment of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, and in cell therapy products which can induce the reduction and destruction of tumors, and the like.
- FIG. 1 is a diagram illustrating the differentiation process from hematopoietic stem cells to mature blood cells
- FIG. 2(a) illustrates the culture composition of the present invention
- FIG. 2(b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention
- FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks
- FIGS. 3 to 5 illustrate results obtained by incubating peripheral blood samples for 28 days under the same conditions using the culture kit of the present invention, into which three groups of peripheral blood samples were poured, immunohistochemistry staining was carried out, and then peripheral blood samples were observed under a microscope (X400) .
- FIGS. 3 to 5 illustrate results obtained by incubating peripheral blood samples for 28 days under the same conditions using the culture kit of the present invention, into which three groups of peripheral blood samples were poured, immunohistochemistry staining was carried out, and then peripheral blood samples were observed under a microscope (X400) .
- FIGS. 3 to 5 illustrate results obtained by incubating peripheral blood samples for 28 days under the same conditions using the culture kit of the present invention, into which three groups of peripheral blood samples were poured, immunohistochemistry staining was carried out, and then peripheral blood samples were observed under a microscope (X400) .
- FIGS. 3 to 5 illustrates the result of immunohistochemistry staining for CD3, and
- FIGb illustrates the result of immuno
- T cells can be obtained from differentiation-completed blood corpuscles in peripheral blood, in particular, leukocytes, by induction.
- activated T lymphocytes which are CD3 and CD25 positive can be obtained from leukocytes obtained from peripheral blood.
- CD3 is a cell marker which is commonly expressed in all T lymphocytes and proves that unknown cells are T cells, and among these T cells, CD25 -expressing T cells are considered to be activated T lymphocytes.
- activated T lymphocytes can be induced from a buffy coat isolated from peripheral blood, and especially, activated T lymphocytes can be induced from leukocytes contained in the buffy coat.
- the culture composition of the present invention comprises adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
- ATP adenosine triphosphate
- G-CSF Granulocyte colony-stimulating factors
- water may be used for the solvent, and preferably, distilled water may be used for the solvent.
- Adenosine triphosphate is also known as ATP, and functions as an energy source for facilitating and maintaining the differentiation into activated T lymphocytes in the culture composition.
- the ATP may be comprised in an amount of 10 to 15 mg, and preferably, 11 to 13 mg, based on the final volume of the culture composition of the present invention being 8 cc. Where the ATP is comprised in an amount of less than 10 mg, there may be a problem in which the directed incubation into activated T lymphocytes may not be carried out sufficiently, and where the ATP is comprised in an amount of more than 15 mg, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than activated T lymphocytes .
- the divalent cation is a component designed to stabilize cell membrane and balance electrolytes in the culture composition of the present invention, and may be one or more selected from the group consisting of Zn + , Cu 2+ , g 2+ , and Cr 2+ , and preferably, Zn + .
- the divalent cation may be included as an appropriate salt known to the art, including sulfates, citrates, and the like such as copper sulfate, magnesium sulfate, zinc sulfate, and the like.
- each component may be used alone, or two or more components may be used in combination.
- the divalent cation may be comprised in an amount of 5 to 7 mg, and preferably, 5.2 to 6.6 mg, based on the final volume of the culture composition of the present invention being 8 cc.
- the divalent cation is comprised in an amount of less than 5 mg, there may be a problem in which the directed differentiation into activated T lymphocytes may be insufficient. Where the divalent cation is comprised in an amount of more than 7 mg, there is a concern that cells may die due to high osmotic pressure in a culture medium.
- the chloride comprised in the present invention plays a role in stabilizing cations and maintaining a suitable concentration of a culture medium in the culture composition.
- the chloride may ⁇ be one or more selected from the group consisting of potassium chloride and bromine chloride, and preferably, potassium chloride .
- the chloride may be comprised in an amount of 100 to 200 mg, and preferably, 130 to 170 mg, based on the final volume of the culture composition of the present invention being 8 cc.
- the chloride is comprised in an amount of less than 100 mg, there may be a problem in which the osmotic pressure is lowered too far and where the chloride is comprised in an amount of more than 200 mg, there may be a problem in which the osmotic pressure is raised too high.
- the osmotic pressure is lowered or raised by too much as above, it may have adverse affects on a cell culture, and the induction of activated T lymphocytes may not be achieved smoothly.
- the vitamin B may be vitamin B6 (pyridoxine) , and the vitamin B acts as a catalyst for cell division in the culture composition.
- the vitamin B may be comprised in an amount of 45 to 55 mg, and preferably, 48 to 52 mg, based on the final volume of the culture composition of the present invention being 8 cc.
- vitamin B6 is comprised in an amount of less than 45 mg, there is a problem with the efficiency of cell division and differentiation, and where vitamin B6 is comprised in an amount of more than 55 mg, there is a concern for an occurrence of cytotoxicity.
- Insulin acts as a messenger for cell differentiation in the culture composition, and R (Regular) insulin may be used for the insulin.
- R Regular insulin
- the insulin may be comprised in an amount of 3 to 7 I.U., and preferably, 4 to 6 I.U. , based on the final volume of the culture composition of the present invention being 8 cc.
- the insulin is comprised in an amount of less than 3 I.U., there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the insulin is comprised in an amount of more than 7 I.U., there is a possibility of an occurrence of cell overproliferation and apoptosis.
- G-CSF Granulocyte colony-stimulating factors
- filgrastim act as a messenger for inducing differentiation in the cell differentiation process, and recombinant G-CSF may be used for the G-CSF.
- the G-CSF may be comprised in an amount of 5 to 15 ⁇ ig, and preferably, 8 to 12 ⁇ , based on the final volume of the culture composition of the present invention being 8 cc.
- the G-CSF is comprised in an amount of less than 5 g, there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the G-CSF is comprised in an amount of more than 15 pg, there is concern for an occurrence of cell overproliferation and apoptosis.
- the erythropoietin also plays a role in inducing differentiation in the cell differentiation process, and recombinant erythropoietin may be used for the erythropoietin.
- the erythropoietin may be comprised in an amount of 5 to 15 I.U., and preferably, 8 to 12 I.U., based on the final volume of the culture composition of the present invention being 8 cc.
- the erythropoietin is comprised in an amount of less than 5 I .U.
- the efficiency of cell division and differentiation may be deteriorated
- the erythropoietin is comprised in an amount of more than 15 I .U.
- the culture composition of the present invention may comprise 10-15 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 80-100 mg of the chloride, 45-55 mg of vitamin B, 3-7 I.U. of insulin, 5-15 ⁇ of Granulocyte colony-stimulating factors (G-CSF) , 5-15 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc.
- ATP adenosine triphosphate
- G-CSF Granulocyte colony-stimulating factors
- the culture kit of the present invention comprises an airtight container containing the above described culture composition of the present invention.
- the culture kit may comprise an airtight sterile container, in which internal pressure is controlled to be equal to external pressure thereof .
- a container usable for the culture kit of the present invention may be a sterilized airtight container.
- Materials for the container are not particularly limited, and any container suitable for culture growth may be usable, and glass may be used for the material of the container.
- any other appropriate container known to the art, which can safely contain the culture composition and allow cells to be cultured, may be used.
- Most preferably, vials may be used for the container.
- the container may contain the culture composition of the present invention in an amount from about 7/50 to about 9/50 of the overall volume.
- the method of the present invention uses the above culture composition and the culture kit of the present invention, and more particularly, comprises mixing peripheral blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into the airtight sterile container, which contains the culture composition of the present invention, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
- the culture composition and the culture kit comprising the same, which are used for the method for inducing activated T lymphocytes from peripheral blood of the present invention, are the same as described above.
- the blood is mixed with an anticoagulant, followed by centrifuging to obtain a buffy coat and plasma.
- the blood may be peripheral blood, which is obtained from the periphery of the human body.
- the peripheral blood may be more preferably obtained from a vein.
- the peripheral blood may be obtained from veins in arms, legs or other extremities .
- the usable anticoagulant may be, but not limited to, one or more selected from the group of sodium citrate and heparin.
- the anticoagulant may be mixed in a ratio of 6 to 7 parts by weight, and preferably, about 6.6 parts by weight, based on 100 parts by weight of peripheral blood. Where the anticoagulant is mixed in a ratio of less than 6 parts by weight based on 100 parts by weight of peripheral blood, the anticoagulant effect may be insufficient, and where the anticoagulant is mixed in a ratio of more than 7 parts by weight, there may be a problem in which citrate toxicity may occur.
- the centrifugation for separating blood components may be carried out in a range of 1500 to 1700 rpm for 20 to 25 minutes, and more preferably, in a range of 1600 to 1700 rpm for 22 to 24 minutes .
- centrifugation is carried out at less than 1500 rpm or for less than 20 minutes, there may be a problem in which the centrifugation may be carried out insufficiently. Where the centrifugation is carried out at more than 1700 rpm or for more than 25 minutes, there is a concern that cells may be damaged.
- the bottom layer occupies about 45%, and is comprised of erythrocytes (red blood cells) .
- the middle layer occupies about 1%, and is comprised of leukocytes (white blood cells) and platelets , and known as a x buffy coat' .
- the topmost layer occupies about 54%, and is comprised of plasma.
- the buffy coat layer and the plasma layer isolated in the centrifugation detailed above are poured.
- External pressure refers to atmospheric pressure, and the method for controlling the pressure may be carried out by, for example, penetrating a syringe needle into a rubber stopper (rubber packing) , followed by removing the syringe needle if the pressures are in equilibrium but is not limited thereto.
- the buffy coat layer and the plasma layer- poured container are incubated in a low temperature incubator.
- the low temperature incubation may be carried out for 50 to 200 hours, and preferably, for 70 to 160 hours . Where the incubation is carried out for less than 50 hours, there may be a problem in which the incubation may be insufficient. Where the incubation is carried out for more than 200 hours, there may be a problem in which cell concentration may increase excessively in the culture composition and thus, apoptosis or cell suicide may occur.
- the incubation may be carried out at a temperature from 37 to 39 °C, and more preferably, at about 38 °C. Where the incubation is carried out at a temperature less than 37 °C, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than activated T lymphocytes. Where the incubation is carried out at more than 39 °C, there is a concern of an occurrence of cell damage from heat.
- the mixed solution was centrifuged at 1670 rpm for 24 minutes , and from the separated blood, a buffy coat and plasma were collected with a pipette, and poured into a culture kit, an airtight 50 cc glass bottle.
- the culture composition comprising the following components described in Table 1 was contained in the culture kit, and distilled water was added as a solvent thereto to make up the final volume of the whole composition to 8 cc.
- a 27 gauge syringe was inserted into a rubber stopper (rubber packing) on the airtight glass bottle, and removed if the pressures were in equilibrium to allow internal and external pressures to be equal .
- FIG. 2(a) illustrates the culture composition of the present invention
- FIG. 2(b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention
- FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks.
- each sample contained in each culture kit was aspirated by a syringe and placed into a 10 mL test tube. Then, each tube was centrifuged at 3000 rpm for 10 minutes at room temperature, and pellets that sank to the bottom and were isolated were collected and embedded in paraffin to be fixed in 10% formalin solution. Cell blocks embedded in paraffin were formed, and then, to perform a hematoxylin-eosin staining, sections for each sample were prepared, and immunohistochemistry staining was carried out. Bond-MAX (Leica) equipment was used in immunohistochemistry staining.
- a list of antibodies in the immunofluorescent experiment for confirming the cell differentiation into activated T lymphocytes is CD3 and CD25. Markers for immunohistochemistry staining used in this experiment were as per the following Table 2.
- FIGS. 3 to 5 (a) illustrates the result of immunohistochemistry staining for CD3, and (b) illustrates the result of immunohistochemistry staining for CD25.
- lymphoid cell marker CD3 was expressed and CD25 was also expressed. This indicates that activated T lymphocytes are obtained by the present invention. Experiment for three groups showed the same results .
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to a culture composition for inducing T cells from peripheral blood, a culture kit comprising the same, and a method for inducing T cells from peripheral blood using the same, and more particularly, to a culture composition for inducing activated T lymphocytes from peripheral blood, comprising adenosine triphosphate (ATP), a divalent cation, a chloride, vitamin B6, insulin, Granulocyte colony-stimulating factors (G-CSF), erythropoietin, and a solvent, a culture kit comprising the same, and a method for inducing activated T lymphocytes from peripheral blood using the same.
Description
[DESCRIPTION]
[invention Title]
CULTURE COMPOSITION FOR INDUCING ACTIVATED T LYMPHOCYTES FROM PERIPHERAL BLOOD, CULTURE KIT COMPRISING THE SAME, AND METHOD FOR INDUCING ACTIVATED T LYMPHOCYTES FROM PERIPHERAL BLOOD USING THE SAME
[Technical Field]
[0001] This application claims the priority of Korean Patent Application No. 10-2012-0073803 filed on July 06, 2012, in the Korean Intellectual Property Office, the disclosure of which is incorporated herein by reference.
[0002] The present invention relates to a culture composition for inducing activated T lymphocytes from peripheral blood, a culture kit comprising the same, and a method for inducing activated T lymphocytes from peripheral blood using the same, and more particularly, to a culture composition for inducing CD3 and CD25 positive T cells by the directed differentiation of leukocytes obtained from peripheral blood, a culture kit comprising the same, and a method for inducing CD3 and CD25 positive T cells using the same .
[Background Art]
[0003] T cells, also known as T lymphocytes, are derived from hematopoietic stem cells in bone marrow, differentiate in the thymus and migrate to peripheral lymphatic tissues . T cells are
distributed in the spleen and all parts of the thymus in lymph nodes .
[0004] T cells occupy 60-70% of lymphocytes in tissues or blood and the number of T cells is commonly slightly greater than that of B cells. While T cells cannot be morphologically distinguished from B cells, they can be identified and isolated by differences in cell surface antigens (CD4, CD8, CD3, or Thyl antigens in mice, and the like) .
[0005] T cells are classified largely into CD4+CD8" T cells and CD4"CD8+ T cells according to antigenic CD4 and CD8 molecules expressed on their surface. T cells are divided into several subgroups having different functions, including helper T cells and cells mediating delayed type hypersensitivity, belonging to the former, and killer T cells belonging to the latter, and the like.
[0006] CD3 is a cell marker which is commonly expressed in all T lymphocytes and proves that unknown cells are T cells. Among these T cells, CD25-expressing T cells are considered to be activated T lymphocytes (T cell subsets: A synopsis of the lecture by Dr. Steve Cobbold for the FHS Physiology Immunology Option 1/ Definitions and relationships of different T cell subsets http: //users .path. ox. ac . uk/~scobbold/Teaching/TSUBSETS .pdf) .
Meanwhile, CD25-positive cells are activated T lymphocytes, and are known to have therapeutic effects on autoimmune diseases and tumors (Romagnoli Paola, Tellier Julie, Van Meerwijik Joost Pm: Genetic control of thymic development of CD4+, CD25+FoxP3+ regulatory T lymphocytes, Eur J Immunol, 2005 Dec; 35 (12) :3525-32) .
[0007] T cells (T-Lymphocytes) are a major type of cells mediating cellular immunity against cancer cells, viruses, or transplanted
tissues or cells. In order to attack targets, T cells should be activated from a resting and nonproliferative state to an active and proliferatable state.
[0008] Meanwhile, hematopoiesis in the human body is a one-way process of differentiation from multipotential hematopoietic stem cells to functional mature differentiated cells, such as granulocytes, monocytes, lymphocytes, and the like, as shown in FIG. 1. [Disclosure]
[Technical Problem]
[0009] Thus, if it is possible to direct differentiation-completed peripheral blood, in particular, mature leukocytes, to differentiate activated T lymphocytes, it is expected that after directed incubation of activated T lymphocytes in vitro has been successfully undertaken, research and clinical applications undertaken with activated T lymphocytes will be practicable in various fields associated with the treatment of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, anticancer vaccines, cell therapy products, and other diseases.
[Technical Solution]
[0010] An aspect of the present invention provides a culture composition for inducing activated T lymphocytes from peripheral blood.
[0011] Another aspect of the present invention provides a culture kit for inducing activated T lymphocytes from peripheral blood.
[0012] Another aspect of the present invention provides a method for inducing activated T lymphocytes using the culture composition and the culture kit.
[0013] According to an aspect of the present invention, there is provided a culture composition for inducing activated T lymphocytes from peripheral blood, comprising adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
[0014] The induced T cells may be CD3 and CD25 cell marker positive .
[0015] The divalent cation may be one or more selected from the group consisting of Zn2+, Cu2+, Mg2+, and Cr2+.
[0016] The chloride may be one or more selected from the group consisting of potassium chloride and bromine chloride.
[0017] The vitamin B may be vitamin B6.
[0018] The solvent may be distilled water.
[0019] The culture composition may comprise 10-15 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 80-100 mg of the chloride, 45-55 mg of vitamin B, 3-7 I.U. of insulin, 5-15 g of Granulocyte colony-stimulating factors (G-CSF), 5-15 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc .
[0020] According to another aspect of the present invention, there is provided a culture kit for inducing activated T lymphocytes from peripheral blood, comprising an airtight sterile container, which contains the above culture composition, and in which internal pressure is controlled to be equal to external pressure thereof.
[0021] According to another aspect of the present invention, there
is provided a method for inducing activated T lymphocytes from peripheral blood, comprising: mixing blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into an airtight sterile container, which contains the culture composition, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
[0022 ] The incubation may be carried out for a period of f om about 50 hours to about 200 hours.
[0023 ] The incubation may be carried out at a temperature from about 37 to 39 °C.
[0024] The induced T cells may be CD3 and CD25 cell marker positive .
[Advantageous Effects]
[0025] With the culture composition, the culture kit of the present invention for inducing activated T lymphocytes from peripheral blood, and the method for inducing activated T lymphocytes using the same, a large amount of activated T lymphocytes can easily be obtained from peripheral blood obtained from adults. Thus, the obtained activated T lymphocytes can be used in various fields associated with the treatment of autoimmune diseases such as rheumatoid arthritis or systemic lupus erythematosus, and in cell therapy products which can induce the reduction and destruction of tumors, and the like.
[Description of Drawings]
[0026] The above and other aspects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:
FIG. 1 is a diagram illustrating the differentiation process from hematopoietic stem cells to mature blood cells;
FIG. 2(a) illustrates the culture composition of the present invention, FIG. 2(b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention, and FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks; and
FIGS. 3 to 5 illustrate results obtained by incubating peripheral blood samples for 28 days under the same conditions using the culture kit of the present invention, into which three groups of peripheral blood samples were poured, immunohistochemistry staining was carried out, and then peripheral blood samples were observed under a microscope (X400) . In respective FIGS. 3 to 5, (a) illustrates the result of immunohistochemistry staining for CD3, and (b) illustrates the result of immunohistochemistry staining for CD25.
[Best Mode]
[0027] Exemplary embodiments of the present invention will now be described in detail with reference to the accompanying drawings.
[0028] According to the present invention, there is provided a culture composition for inducing activated T lymphocytes from
peripheral blood. According to the culture composition of the present invention, T cells can be obtained from differentiation-completed blood corpuscles in peripheral blood, in particular, leukocytes, by induction.
[0029] According to the present invention, activated T lymphocytes which are CD3 and CD25 positive can be obtained from leukocytes obtained from peripheral blood. CD3 is a cell marker which is commonly expressed in all T lymphocytes and proves that unknown cells are T cells, and among these T cells, CD25 -expressing T cells are considered to be activated T lymphocytes.
[0030] More particularly, according to the present invention, activated T lymphocytes can be induced from a buffy coat isolated from peripheral blood, and especially, activated T lymphocytes can be induced from leukocytes contained in the buffy coat.
[0031] The culture composition of the present invention comprises adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
[0032] In the present invention, water may be used for the solvent, and preferably, distilled water may be used for the solvent.
[0033] Adenosine triphosphate is also known as ATP, and functions as an energy source for facilitating and maintaining the differentiation into activated T lymphocytes in the culture composition.
[0034] The ATP may be comprised in an amount of 10 to 15 mg, and preferably, 11 to 13 mg, based on the final volume of the culture composition of the present invention being 8 cc. Where the ATP is
comprised in an amount of less than 10 mg, there may be a problem in which the directed incubation into activated T lymphocytes may not be carried out sufficiently, and where the ATP is comprised in an amount of more than 15 mg, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than activated T lymphocytes .
[0035] The divalent cation is a component designed to stabilize cell membrane and balance electrolytes in the culture composition of the present invention, and may be one or more selected from the group consisting of Zn+, Cu2+, g2+, and Cr2+, and preferably, Zn+. The divalent cation may be included as an appropriate salt known to the art, including sulfates, citrates, and the like such as copper sulfate, magnesium sulfate, zinc sulfate, and the like.
[0036] In the present invention, the term 'one or more' means that each component may be used alone, or two or more components may be used in combination.
[0037 ] The divalent cation may be comprised in an amount of 5 to 7 mg, and preferably, 5.2 to 6.6 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0038] Where the divalent cation is comprised in an amount of less than 5 mg, there may be a problem in which the directed differentiation into activated T lymphocytes may be insufficient. Where the divalent cation is comprised in an amount of more than 7 mg, there is a concern that cells may die due to high osmotic pressure in a culture medium.
[0039] The chloride comprised in the present invention plays a role in stabilizing cations and maintaining a suitable concentration
of a culture medium in the culture composition. The chloride may¬ be one or more selected from the group consisting of potassium chloride and bromine chloride, and preferably, potassium chloride .
[0040] The chloride may be comprised in an amount of 100 to 200 mg, and preferably, 130 to 170 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0041] Where the chloride is comprised in an amount of less than 100 mg, there may be a problem in which the osmotic pressure is lowered too far and where the chloride is comprised in an amount of more than 200 mg, there may be a problem in which the osmotic pressure is raised too high. When the osmotic pressure is lowered or raised by too much as above, it may have adverse affects on a cell culture, and the induction of activated T lymphocytes may not be achieved smoothly.
[0042] The vitamin B may be vitamin B6 (pyridoxine) , and the vitamin B acts as a catalyst for cell division in the culture composition.
[0043] The vitamin B may be comprised in an amount of 45 to 55 mg, and preferably, 48 to 52 mg, based on the final volume of the culture composition of the present invention being 8 cc.
[0044] Where vitamin B6 is comprised in an amount of less than 45 mg, there is a problem with the efficiency of cell division and differentiation, and where vitamin B6 is comprised in an amount of more than 55 mg, there is a concern for an occurrence of cytotoxicity.
[0045] Insulin acts as a messenger for cell differentiation in the culture composition, and R (Regular) insulin may be used for the insulin.
[0046] The insulin may be comprised in an amount of 3 to 7 I.U., and preferably, 4 to 6 I.U. , based on the final volume of the culture composition of the present invention being 8 cc.
[0047] Where the insulin is comprised in an amount of less than 3 I.U., there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the insulin is comprised in an amount of more than 7 I.U., there is a possibility of an occurrence of cell overproliferation and apoptosis.
[0048] Granulocyte colony-stimulating factors (G-CSF) , also known as filgrastim, act as a messenger for inducing differentiation in the cell differentiation process, and recombinant G-CSF may be used for the G-CSF.
[0049] The G-CSF may be comprised in an amount of 5 to 15 \ig, and preferably, 8 to 12 μς, based on the final volume of the culture composition of the present invention being 8 cc.
[0050] Where the G-CSF is comprised in an amount of less than 5 g, there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the G-CSF is comprised in an amount of more than 15 pg, there is concern for an occurrence of cell overproliferation and apoptosis.
[0051] The erythropoietin also plays a role in inducing differentiation in the cell differentiation process, and recombinant erythropoietin may be used for the erythropoietin.
[0052] The erythropoietin may be comprised in an amount of 5 to 15 I.U., and preferably, 8 to 12 I.U., based on the final volume of the culture composition of the present invention being 8 cc.
[0053] Where the erythropoietin is comprised in an amount of less than 5 I .U. , there may be a problem in which the efficiency of cell division and differentiation may be deteriorated, and where the erythropoietin is comprised in an amount of more than 15 I .U. , there is a concern for an occurrence of cell overproliferation and apoptosis .
[0054] Most preferably, the culture composition of the present invention may comprise 10-15 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 80-100 mg of the chloride, 45-55 mg of vitamin B, 3-7 I.U. of insulin, 5-15 μς of Granulocyte colony-stimulating factors (G-CSF) , 5-15 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc.
[0055] Meanwhile, according to the present invention, there is provided a culture kit for inducing activated T lymphocytes from peripheral blood. The culture kit of the present invention comprises an airtight container containing the above described culture composition of the present invention.
[0056] Furthermore, the culture kit may comprise an airtight sterile container, in which internal pressure is controlled to be equal to external pressure thereof .
[0057] A container usable for the culture kit of the present invention may be a sterilized airtight container. Materials for the container are not particularly limited, and any container suitable for culture growth may be usable, and glass may be used for the material of the container. However, any other appropriate container known to the art, which can safely contain the culture
composition and allow cells to be cultured, may be used. Most preferably, vials may be used for the container.
[0058] The container may contain the culture composition of the present invention in an amount from about 7/50 to about 9/50 of the overall volume.
[0059] Furthermore, according to the present invention, there is provided a method for inducing activated T lymphocytes from peripheral blood.
[0060] The method of the present invention uses the above culture composition and the culture kit of the present invention, and more particularly, comprises mixing peripheral blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma; pouring the obtained buffy coat and plasma into the airtight sterile container, which contains the culture composition of the present invention, and in which internal pressure is controlled to be equal to external pressure thereof; and inserting the buffy coat and plasma poured container into a low temperature incubator and incubating the buffy coat and plasma.
[0061] The culture composition and the culture kit comprising the same, which are used for the method for inducing activated T lymphocytes from peripheral blood of the present invention, are the same as described above.
[0062] More particularly, for the method for inducing activated T lymphocytes of the present invention, first, in order to prevent the coagulation of blood obtained from humans, the blood is mixed with an anticoagulant, followed by centrifuging to obtain a buffy coat and plasma.
[0063 ] Here, the blood may be peripheral blood, which is obtained from the periphery of the human body. The peripheral blood may be more preferably obtained from a vein. For example, the peripheral blood may be obtained from veins in arms, legs or other extremities .
[0064 ] Here, the usable anticoagulant may be, but not limited to, one or more selected from the group of sodium citrate and heparin.
[0065] The anticoagulant may be mixed in a ratio of 6 to 7 parts by weight, and preferably, about 6.6 parts by weight, based on 100 parts by weight of peripheral blood. Where the anticoagulant is mixed in a ratio of less than 6 parts by weight based on 100 parts by weight of peripheral blood, the anticoagulant effect may be insufficient, and where the anticoagulant is mixed in a ratio of more than 7 parts by weight, there may be a problem in which citrate toxicity may occur.
[0066] The centrifugation for separating blood components may be carried out in a range of 1500 to 1700 rpm for 20 to 25 minutes, and more preferably, in a range of 1600 to 1700 rpm for 22 to 24 minutes .
[0067] Where the centrifugation is carried out at less than 1500 rpm or for less than 20 minutes, there may be a problem in which the centrifugation may be carried out insufficiently. Where the centrifugation is carried out at more than 1700 rpm or for more than 25 minutes, there is a concern that cells may be damaged.
[0068] Once the centrifugation is completed, blood is divided into three layers. The bottom layer occupies about 45%, and is comprised of erythrocytes (red blood cells) . The middle layer occupies about 1%, and is comprised of leukocytes (white blood cells) and platelets ,
and known as a xbuffy coat' . The topmost layer occupies about 54%, and is comprised of plasma.
[0069] Into the airtight sterile container, which contains the culture composition of the present invention, and in which internal pressure is controlled to be equal to external pressure thereof, the buffy coat layer and the plasma layer isolated in the centrifugation detailed above are poured. External pressure refers to atmospheric pressure, and the method for controlling the pressure may be carried out by, for example, penetrating a syringe needle into a rubber stopper (rubber packing) , followed by removing the syringe needle if the pressures are in equilibrium but is not limited thereto.
[0070] Subsequently, the buffy coat layer and the plasma layer- poured container are incubated in a low temperature incubator. Here, the low temperature incubation may be carried out for 50 to 200 hours, and preferably, for 70 to 160 hours . Where the incubation is carried out for less than 50 hours, there may be a problem in which the incubation may be insufficient. Where the incubation is carried out for more than 200 hours, there may be a problem in which cell concentration may increase excessively in the culture composition and thus, apoptosis or cell suicide may occur.
[0071] The incubation may be carried out at a temperature from 37 to 39 °C, and more preferably, at about 38 °C. Where the incubation is carried out at a temperature less than 37 °C, there may be a problem in which the blood corpuscles may differentiate into a type of cell other than activated T lymphocytes. Where the incubation is carried out at more than 39 °C, there is a concern of an occurrence
of cell damage from heat.
[0072] Hereinafter, the present invention will be described in more detail with reference to specific embodiments. However, the following embodiments are described for illustrative purposes only, and do not limit the scope of the present invention.
[Mode for Invention]
[0073] Embodiments
[0074] <Embodiments>
[0075] 1. Preparation of culture kit comprising culture medium
[0076] To prevent coagulation, 30 cc of blood extracted from a vein was mixed with 2 cc of a citrate buffer (2.45 g of dextrose, 2.2 g of sodium citrate, and 730 mg citrate are contained in 100 cc of the citrate buffer) (Fenwal) to prepare a mixed solution.
[0077] The mixed solution was centrifuged at 1670 rpm for 24 minutes , and from the separated blood, a buffy coat and plasma were collected with a pipette, and poured into a culture kit, an airtight 50 cc glass bottle.
[0078] For the buffy coat and plasma obtained by the centrifugation of 30 cc of blood, the culture composition comprising the following components described in Table 1 was contained in the culture kit, and distilled water was added as a solvent thereto to make up the final volume of the whole composition to 8 cc.
[0079] [ Table l]
[0080] A 27 gauge syringe was inserted into a rubber stopper (rubber packing) on the airtight glass bottle, and removed if the pressures were in equilibrium to allow internal and external pressures to be equal .
[0081] FIG. 2(a) illustrates the culture composition of the present invention, FIG. 2(b) illustrates the result directly after pouring the buffy coat and plasma into the culture composition of the present invention, and FIG. 2(c) illustrates the result after incubating the culture kit of the present invention for 4 weeks.
[0082] 2. Induction process of activated T lymphocytes from peripheral blood
[0083] Blood samples were collected from three volunteers. Three groups of the culture kits as prepared in "1." were formed and incubated for 28 days under the same conditions. The incubation temperature was 38 °C.
[0084] 3. Confirmation of results for T cell induction
[0085] (1) Immunohistochemistry staining
[0086] After incubation, each sample contained in each culture kit was aspirated by a syringe and placed into a 10 mL test tube. Then, each tube was centrifuged at 3000 rpm for 10 minutes at room temperature, and pellets that sank to the bottom and were isolated were collected and embedded in paraffin to be fixed in 10% formalin solution. Cell blocks embedded in paraffin were formed, and then, to perform a hematoxylin-eosin staining, sections for each sample were prepared, and immunohistochemistry staining was carried out. Bond-MAX (Leica) equipment was used in immunohistochemistry staining.
[0087] As described above, after the immunohistochemistry staining, observation was made under a microscope (X400) . The results for a first, second, and third group are shown in FIG. 3, FIG. 4, and FIG. 5, respectively.
[0088] A list of antibodies in the immunofluorescent experiment for confirming the cell differentiation into activated T lymphocytes is CD3 and CD25. Markers for immunohistochemistry staining used in this experiment were as per the following Table 2.
[0089] [ Table l]
[0090] Meanwhile, the information on the staining reagent for immunohistochemistry used in this experiment is as follows:
Leica Microsystems
Bond TM Polymer Refine Detection
Catalog No: DS9800
[0091] In FIGS. 3 to 5, (a) illustrates the result of immunohistochemistry staining for CD3, and (b) illustrates the result of immunohistochemistry staining for CD25.
[0092] (2) Conclusion
[0093] Referring to FIGS. 3 to 5, as shown in the above experiment, after 4 weeks of incubation, the lymphoid cell marker CD3 was expressed and CD25 was also expressed. This indicates that activated T lymphocytes are obtained by the present invention. Experiment for three groups showed the same results .
[0094] Referring to FIGS. 3 to 5, as the result of the experiment, cell components having two groups of nuclei comprising a small amount of lymphocyte-like nuclei with a large amount of platelets and a small amount of cytoplasms, and a small amount of lymphocyte or monocyte-like nuclei with a large amount of cytoplasms were identified. Both groups of cells exhibited strong immunoreactivity for both CD3 and CD25.
[0095] That is, this result confirms that activated T lymphocytes were induced' from mature peripheral leukocytes with the use of the culture composition, the culture kit, and the method of the present invention.
[0096] While the present invention has been shown and described in connection with the exemplary embodiments, it will be apparent to those skilled in the art that modifications and variations can
be made without departing from the spirit and scope of the invention as defined by the appended claims.
Claims
[CLAIMS]
[Claim l]
A culture composition for inducing activated T lymphocytes from peripheral blood, comprising adenosine triphosphate (ATP) , a divalent cation, a chloride, vitamin B, insulin, Granulocyte colony-stimulating factors (G-CSF) , erythropoietin, and a solvent.
[Claim 2]
The culture composition of claim 1, wherein the induced activated T cells are CD3 and CD25 cell marker positive.
[Claim 3]
The culture composition of claim 1, wherein the divalent cation is one or more selected from the group consisting of Zn2+, Cu2+, Mg2+, and Cr2+.
[Claim 4]
The culture composition of claim 1, wherein the chloride is one or more selected from the group consisting of potassium chloride and bromine chloride.
[Claim 5]
The culture composition of claim 1, wherein the vitamin B is vitamin B6 (pyridoxine) .
[Claim 6]
The culture composition of claim 1, wherein the solvent is
distilled water. [Claim 7]
The culture composition of claim 1, comprising 10-15 mg of adenosine triphosphate (ATP) , 5-7 mg of the divalent cation, 80-100 mg of the chloride, 45-55 mg of vitamin B, 3-7 I.U. of insulin, 5-15 μς of Granulocyte colony-stimulating factors (G-CSF) , 5-15 I.U. of erythropoietin, and the solvent as a remainder such that a final overall volume is 8 cc.
[Claim 8]
A culture kit for inducing activated T lymphocytes from peripheral blood, comprising an airtight sterile container, which contains the culture composition of any of claims 1 to 7, and in which internal pressure is controlled to be equal to external pressure thereof .
[Claim 9]
A method for inducing activated T lymphocytes from peripheral blood, comprising:
mixing blood with an anticoagulant, centrifuging the blood, and obtaining a buffy coat and plasma;
pouring the obtained buffy coat and plasma into an airtight sterile container, which contains the culture composition of any of claims 1 to 7, and in which internal pressure is controlled to be equal to external pressure thereof; and
inserting the buffy coat and plasma poured container into a
low temperature incubator and incubating the buffy coat and plasma. [Claim 10]
The method of claim 9, wherein the incubation is carried out for a period of from about 50 hours to about 200 hours.
[Claim ll]
The method of claim 9, wherein the incubation is carried out at from about 37 to about 39 °C.
[Claim 12]
The method of claim 9, wherein the induced activated T cells are CD3 and CD25 cell marker positive.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2012-0073803 | 2012-07-06 | ||
KR1020120073803A KR101290062B1 (en) | 2012-07-06 | 2012-07-06 | Culture composition, and culture kit for inducing from peripheral blood to activated t lymphocyte, and method for inducing activated t lymphocyte from peripheral blood using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014007421A1 true WO2014007421A1 (en) | 2014-01-09 |
Family
ID=48998104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2012/006318 WO2014007421A1 (en) | 2012-07-06 | 2012-08-08 | Culture composition for inducing activated t lymphocytes from peripheral blood, culture kit comprising the same, and method for inducing activated t lymphocytes from peripheral blood using the same |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR101290062B1 (en) |
WO (1) | WO2014007421A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114149978A (en) * | 2022-02-09 | 2022-03-08 | 深圳博雅感知药业有限公司 | Method for producing CAR-T cells |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1853110A4 (en) * | 2005-02-28 | 2009-01-14 | Regenetech Inc | Method of providing readily available cellular material derived from peripheral blood and a composition thereof |
-
2012
- 2012-07-06 KR KR1020120073803A patent/KR101290062B1/en active IP Right Grant
- 2012-08-08 WO PCT/KR2012/006318 patent/WO2014007421A1/en active Application Filing
Non-Patent Citations (4)
Title |
---|
BUZZEO, MP. ET AL.: "Hematopoietic stem cell mobilization with G-CSF induce s innate inflammation yet suppresses adaptive immune gene expression as reve aled by microarray analysis", EXPERIMENTAL HEMATOLOGY, vol. 35, 2007, pages 1456 - 1465. * |
FRANZKE, A. ET AL.: "G-CSF as immune regulator in T cells expressing the G- CSF receptor: implications for transplantation and autoimmune diseases", BL OOD, vol. 102, no. 2, 15 July 2003 (2003-07-15), pages 734 - 739 * |
LIU, Q-L. ET AL.: "Effect of insulin on functional status of cord blood-der ived dendritic cells and on dendritic cell-induced CTL cytotoxicity against pancreatic cancer cell lines", HEPATOBILIARY PANCREAT DIS INT, vol. 8, no. 5, 15 October 2009 (2009-10-15), pages 529 - 534 * |
SCHENK, U. ET AL.: "Purinergic Control of T Cell Activation by ATP Released Through Pannexin-1 Hemichannels", SCIENCE SIGNALING, vol. 1.1, no. 39, 30 September 2008 (2008-09-30) * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114149978A (en) * | 2022-02-09 | 2022-03-08 | 深圳博雅感知药业有限公司 | Method for producing CAR-T cells |
CN114149978B (en) * | 2022-02-09 | 2022-04-26 | 深圳博雅感知药业有限公司 | Method for producing CAR-T cells |
Also Published As
Publication number | Publication date |
---|---|
KR101290062B1 (en) | 2013-07-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0289896B1 (en) | A simplified method for the preparation of human lymphokine activated killer cells | |
KR20080018089A (en) | Manufacturing method of activated lymphocytes for immunotherapy | |
JP7332787B2 (en) | In vitro culture, induction, activation and cryopreservation of immune cells and preparation of cell banks thereof | |
US20080014174A1 (en) | Method for treating tumors, infectious diseases, and autoimmune diseases with an activated HLA matching donor-originating lymphocyte | |
US20230277599A1 (en) | Methods of Preserving Mesenchymal Stem Cells | |
US20150328260A1 (en) | Blood cell preparations and related methods (gen 8) | |
CN104039333B (en) | The treatment or prevention method of graft versus host disease | |
JP4917201B2 (en) | Preparations for the prevention and treatment of tumors and various infectious diseases after umbilical cord blood transplantation, formulations for promoting the engraftment of umbilical cord blood stem cells after umbilical cord blood transplantation, formulations for prevention and treatment of tumors and various infectious diseases after umbilical cord blood transplantation, and A method for producing a preparation for engraftment of transplanted cord blood stem cells after cord blood transplantation. | |
JP4389039B2 (en) | PHARMACEUTICAL COMPOSITION CONTAINING ALLOGENIC ACTIVATED CD4-POSITIVE CELLS AS MAIN COMPONENTS, PROCESS FOR PRODUCING THE SAME AND KIT FOR PREPARING THE PHARMACEUTICAL COMPOSITION | |
WO2014007421A1 (en) | Culture composition for inducing activated t lymphocytes from peripheral blood, culture kit comprising the same, and method for inducing activated t lymphocytes from peripheral blood using the same | |
CN111849897B (en) | In vitro activation method for cell factor induced killer cells | |
WO2021167094A1 (en) | Monocyte purification method in peripheral blood raw material collection/freezing-thawing step | |
WO2014007423A1 (en) | Culture composition for inducing dendritic cells from peripheral blood, culture kit comprising the same, and method for inducing dendritic cells from peripheral blood using the same | |
WO2014093845A1 (en) | Point of care isolation and concentration of blood cells | |
CN114085812A (en) | Mesenchymal stem cell population with high expression of CD106 and/or CD142 and reduced expression, and preparation method and application thereof | |
US20190241871A1 (en) | Method for manufacturing natural killer t (nkt) cell - stimulating dendritic cell, method for manufacturing cell composition containing the nkt cell stimulating dendritic cell and nkt cell, and cell composition containing thereof | |
Zhang et al. | Reduced IL-35 levels are associated with increased platelet aggregation and activation in patients with acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation | |
Talmadge et al. | Potential for cytokine and product manipulation to improve the results of autologous stem cell transplantation for rheumatoid arthritis. | |
WO2016201657A1 (en) | Serum replacement for culturing lymphocytes, and preparation method therefor | |
WO2014007422A1 (en) | Composition for preserving platelets, kit for preserving platelets comprising the same, and method for preserving platelets using the same | |
Cruz et al. | Preparation of Extracellular Vesicles from Mesenchymal Stem Cells | |
Lowdell et al. | Processing of cells for transplantation | |
NL2034495A (en) | Stem cell cryopreservation protective agent, preparation method, and application thereof | |
CN115927181A (en) | Preparation method and application of T lymphocytes from pleural effusion and ascites | |
CN103289953A (en) | Fish leukocyte separation method |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12880535 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 12880535 Country of ref document: EP Kind code of ref document: A1 |